Horizon Pharma plc to Participate in Two Conferences in May

DUBLIN, IRELAND--(Marketwired - May 4, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that it will attend and present at the following conferences in May:

• Bank of America Merrill Lynch 2015 Health Care Conference
  • Presentation Date: Tuesday, May 12, 2015
  • Presentation Time: 4:20 p.m. PT (7:20 p.m. ET)
    
    

• 2015 UBS Global Health Care Conference
  • Presentation Date: Monday, May 18, 2015
  • Presentation Time: 1:00 p.m. ET
    
    

The presentations will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available for 10 business days.

About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.

Contacts:

Investor Contact:
John Thomas
Executive Vice President, Strategy and Investor Relations
Email Contact

Media Contact:
Geoff Curtis
Group Vice President, Corporate Communications
Email Contact